Sarepta Therapeutics, Inc. (SRPT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 540 | 702 | 933 | 1,243 | 1,902 | 2,198 | 1,974 | 1,840 |
| Operating profit | $m | -658 | -143 | ||||||
| Net profit | $m | -554 | -419 | -703 | -536 | 235 | -713 | -137 | 339 |
| EPS reported | $ | -7.13 | -2.90 | ||||||
| Operating cashflow per share | $ | -1.96 | -0.87 | ||||||
| Capex per share | $ | 0.97 | 0.38 | ||||||
| FCF per share | $ | -2.93 | -1.25 | ||||||
| Free cash flow | $m | -307 | -131 | ||||||
| Net debt | $m | -111 | 59 | ||||||
| Book value equity | $m | 1,141 | 1,528 | ||||||
| Book value per share | $ | 10.88 | 14.49 | ||||||
| Number of shares | m | 104.79 | 105.43 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.98 | 1.48 | ||||||
| P/S LTM | x | 1.03 | 1.14 | ||||||
| P/FCF LTM | x | -7.33 | -17.15 | ||||||
| EV/EBITDA LTM | x | -3.85 | -170.98 | ||||||
| EV/Sales LTM | x | 1.13 | 1.21 | ||||||
| Earnings Yield LTM | % | -31.63% | -7.16% | ||||||
| FCF Yield | % | -13.63% | -5.83% | ||||||
| Quality | |||||||||
| ROE | % | -62.55% | -9.96% | ||||||
| ROIC | % | -29.03% | -5.33% | ||||||
| Operating margin | % | -29.92% | -7.26% | ||||||
| Gross margin | % | +59.90% | +58.56% | ||||||
| FCF/Sales | % | -13.99% | -6.66% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +15.58% | +3.80% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.30 | -0.13 | ||||||
| Net Debt/EBITDA | x | -0.37 | -32.55 | ||||||
| EBIT/Net interest | x | -67.60 | -2.45 | ||||||
| Net debt/market cap | % | +36.76% | +44.36% | ||||||
| Net debt/Equity | x | -0.10 | 0.04 | ||||||
| Gross debt/equity | x | 0.91 | 0.68 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Sarepta Therapeutics, Inc. (SRPT)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free